Toei Shinyaku Co., Ltd. announced the publication of a peer-reviewed veterinary study on outdoor-cultivated Agaricus brasiliensis KA21 involving dogs with Malassezia dermatitis.
The study was conducted in collaboration with the Department of Immunology, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, and examined changes in serum anti-β-glucan antibody titers and clinical symptoms in dogs receiving Agaricus KA21.
Nine dogs with Malassezia dermatitis were included in the study. In the group not receiving oral steroids, anti-β-glucan antibody titers increased in most dogs after Agaricus KA21 intake, and dogs showing improvement in clinical symptoms also showed increased antibody titers. The authors reported that these findings suggest a possible relationship between Agaricus KA21 intake, anti-β-glucan antibody responses, and clinical symptoms in canine Malassezia dermatitis.
The paper was published in the International Journal of Medicinal Mushrooms and represents the 33rd international scientific paper related to Agaricus KA21 reported by Toei Shinyaku.
Toei Shinyaku continues to conduct veterinary and immunological research on outdoor-cultivated Agaricus KA21 in collaboration with universities, veterinary hospitals, and research institutions.
Details
Paper Title: Effects of Outdoor-Grown Royal Sun Medicinal Mushroom Agaricus brasiliensis KA21 (Agaricomycetes) Fruiting Body on Canine Malassezia Dermatitis
Journal: International Journal of Medicinal Mushrooms
Citation: 26(6):13-23 (2024)
PubMed: PMID 38801085
Related Links
PubMed: https://pubmed.ncbi.nlm.nih.gov/38801085/
Press Release
English：https://en.atpress.com/news/395709
Japanese：https://www.atpress.ne.jp/news/395709
Chinese：https://zh.atpress.com/news/395709
